{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:00:58Z","timestamp":1792879258642,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-024-03699-z","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T11:02:26Z","timestamp":1729681346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination"],"prefix":"10.1186","volume":"22","author":[{"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-9230","authenticated-orcid":false,"given":"Micha\u0142","family":"Brzd\u0119k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Tronina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Janocha-Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Klapaczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Parfieniuk-Kowerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sobala-Szczygie\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Laurans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"3699_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3748\/wjg.v29.i6.949","volume":"29","author":"M Brzd\u0119k","year":"2023","unstructured":"Brzd\u0119k M, Zar\u0119bska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J Gastroenterol. 2023;29:949\u201366.","journal-title":"World J Gastroenterol"},{"key":"3699_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/liv.14324","volume":"40","author":"H Razavi","year":"2020","unstructured":"Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40:522\u20139.","journal-title":"Liver Int"},{"key":"3699_CR3","unstructured":"Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 26 Aug 2024."},{"key":"3699_CR4","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low-and middle-income countries. World Health Organization; 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376461\/9789240091672-eng.pdf?sequence=1."},{"key":"3699_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12879-023-08169-0","volume":"23","author":"MLG Ferraz","year":"2023","unstructured":"Ferraz MLG, de Andrade ARCF, Pereira GHS, Codes L, Bittencourt PL. Retrieval of HCV patients lost to follow-up as a strategy for Hepatitis C Microelimination: results of a Brazilian multicentre study. BMC Infect Dis. 2023;23:468.","journal-title":"BMC Infect Dis"},{"key":"3699_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/liv.15729","volume":"44","author":"M van Dijk","year":"2024","unstructured":"van Dijk M, Boyd A, Brakenhoff SM, Isfordink CJ, van Zoest RA, Verhagen MD, et al. Socio-economic factors associated with loss to follow-up among individuals with HCV: a Dutch nationwide cross-sectional study. Liver Int. 2024;44:52\u201360.","journal-title":"Liver Int"},{"key":"3699_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/jvh.13399","volume":"27","author":"M van Dijk","year":"2020","unstructured":"van Dijk M, Drenth JPH, HepNed study group. Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination. J Viral Hepat. 2020;27:1270\u201383.","journal-title":"J Viral Hepat."},{"key":"3699_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/v14010096","volume":"14","author":"P Pabjan","year":"2022","unstructured":"Pabjan P, Brzd\u0119k M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, et al. Are there still difficult-to-treat patients with chronic hepatitis C in the era of direct-acting antivirals? Viruses. 2022;14:96.","journal-title":"Viruses"},{"key":"3699_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10620-022-07483-y","volume":"68","author":"PJ Clark","year":"2023","unstructured":"Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson AJ, Levy M, et al. Liver disease and poor adherence limit hepatitis C cure: a real-world Australian treatment cohort. Dig Dis Sci. 2023;68:291\u2013303.","journal-title":"Dig Dis Sci"},{"key":"3699_CR10","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.3748\/wjg.v26.i43.6770","volume":"26","author":"CM Muzica","year":"2020","unstructured":"Muzica CM, Stanciu C, Huiban L, Singeap A-M, Sfarti C, Zenovia S, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end. World J Gastroenterol. 2020;26:6770\u201381.","journal-title":"World J Gastroenterol"},{"key":"3699_CR11","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.3390\/cancers13153694","volume":"13","author":"R Flisiak","year":"2021","unstructured":"Flisiak R, Zar\u0119bska-Michaluk D, Janczewska E, \u0141api\u0144ski T, Rogalska M, Karpi\u0144ska E, et al. Five-year follow-up of cured HCV patients under real-world interferon-free therapy. Cancers (Basel). 2021;13:3694.","journal-title":"Cancers (Basel)"},{"key":"3699_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5114\/ceh.2017.67782","volume":"2","author":"W Halota","year":"2017","unstructured":"Halota W, Flisiak R, Juszczyk J, Ma\u0142kowski P, Paw\u0142owska M, Simon K, et al. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol. 2017;2:47\u201355.","journal-title":"Clin Exp Hepatol"},{"key":"3699_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5114\/ceh.2020.98606","volume":"6","author":"W Halota","year":"2020","unstructured":"Halota W, Flisiak R, Juszczyk J, Ma\u0142kowski P, Paw\u0142owska M, Simon K, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. Clin Exp Hepatol. 2020;6:163\u20139.","journal-title":"Clin Exp Hepatol"},{"key":"3699_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/ceh.2023.125957","volume":"9","author":"K Tomasiewicz","year":"2023","unstructured":"Tomasiewicz K, Flisiak R, Jaroszewicz J, Ma\u0142kowski P, Paw\u0142owska M, Piekarska A, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023. Clin Exp Hepatol. 2023;9:1\u20138.","journal-title":"Clin Exp Hepatol"},{"key":"3699_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/hep.25936","volume":"56","author":"G Ferraioli","year":"2012","unstructured":"Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology. 2012;56:2125\u201333.","journal-title":"Hepatology"},{"key":"3699_CR16","first-page":"163","volume":"130","author":"R Flisiak","year":"2020","unstructured":"Flisiak R, Zar\u0119bska-Michaluk D, Jaroszewicz J, Lorenc B, Klapaczy\u0144ski J, Tudrujek-Zdunek M, et al. Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection. Pol Arch Intern Med. 2020;130:163\u201372.","journal-title":"Pol Arch Intern Med"},{"key":"3699_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/medicina56030101","volume":"56","author":"V Scaglione","year":"2020","unstructured":"Scaglione V, Mazzitelli M, Costa C, Pisani V, Greco G, Serapide F, et al. Virological and clinical outcome of DAA containing regimens in a cohort of patients in Calabria region (Southern Italy). Medicina (Kaunas). 2020;56:101.","journal-title":"Medicina (Kaunas)"},{"key":"3699_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2018.06.019","volume":"59","author":"S Nouch","year":"2018","unstructured":"Nouch S, Gallagher L, Erickson M, Elbaharia R, Zhang W, Wang L, et al. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver. Canada Int J Drug Policy. 2018;59:76\u201384.","journal-title":"Canada Int J Drug Policy"},{"key":"3699_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jgh3.12855","volume":"7","author":"A Kuwano","year":"2023","unstructured":"Kuwano A, Yada M, Kurosaka K, Tanaka K, Masumoto A, Motomura K. Risk factors for loss to follow-up after the start of direct-acting antiviral treatment for hepatitis C virus infection. JGH Open. 2023;7:98\u2013104.","journal-title":"JGH Open"},{"key":"3699_CR20","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/add.14128","volume":"113","author":"S Christensen","year":"2018","unstructured":"Christensen S, Buggisch P, Mauss S, B\u00f6ker KHW, Schott E, Klinker H, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction. 2018;113:868\u201382.","journal-title":"Addiction"},{"key":"3699_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12876-022-02416-5","volume":"22","author":"PJ Clark","year":"2022","unstructured":"Clark PJ, Valery PC, Ward J, Strasser SI, Weltman M, Thompson A, et al. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up. BMC Gastroenterol. 2022;22:339.","journal-title":"BMC Gastroenterol"},{"key":"3699_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","volume":"169","author":"JI Tsui","year":"2016","unstructured":"Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016;169:101\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"3699_CR23","doi-asserted-by":"publisher","first-page":"105742","DOI":"10.1016\/j.antiviral.2023.105742","volume":"220","author":"D Zar\u0119bska-Michaluk","year":"2023","unstructured":"Zar\u0119bska-Michaluk D, Flisiak R, Janczewska E, Berak H, Mazur W, Janocha-Litwin J, et al. Does a detectable HCV RNA at the end of DAA therapy herald treatment failure? Antiviral Res. 2023;220:105742.","journal-title":"Antiviral Res"},{"key":"3699_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/hep4.1826","volume":"6","author":"J Yee","year":"2022","unstructured":"Yee J, Carson JM, Hajarizadeh B, Hanson J, O\u2019Beirne J, Iser D, et al. High Effectiveness of broad access direct-acting antiviral therapy for hepatitis C in an Australian real-world cohort: the REACH-C study. Hepatol Commun. 2022;6:496\u2013512.","journal-title":"Hepatol Commun"},{"key":"3699_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jgh.16440","volume":"39","author":"PJ Clark","year":"2024","unstructured":"Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson A, Levy MT, et al. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care. J Gastroenterol Hepatol. 2024;39:568\u201375.","journal-title":"J Gastroenterol Hepatol"},{"key":"3699_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/jvh.13228","volume":"27","author":"M Darvishian","year":"2020","unstructured":"Darvishian M, Wong S, Binka M, Yu A, Ramji A, Yoshida EM, et al. Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat. 2020;27:243\u201360.","journal-title":"J Viral Hepat"},{"key":"3699_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","volume":"71","author":"J Mac\u00edas","year":"2019","unstructured":"Mac\u00edas J, Morano LE, T\u00e9llez F, Granados R, Rivero-Ju\u00e1rez A, Palacios R, et al. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. J Hepatol. 2019;71:45\u201351.","journal-title":"J Hepatol"},{"key":"3699_CR28","doi-asserted-by":"publisher","first-page":"835836","DOI":"10.3389\/fpubh.2022.835836","volume":"10","author":"P Mateu-Gelabert","year":"2022","unstructured":"Mateu-Gelabert P, Sabounchi NS, Guarino H, Ciervo C, Joseph K, Eckhardt BJ, et al. Hepatitis C virus risk among young people who inject drugs. Front Public Health. 2022;10:835836.","journal-title":"Front Public Health"},{"key":"3699_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2020.11.027","volume":"74","author":"T Kushner","year":"2021","unstructured":"Kushner T, Reau N. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021;74:734\u201341.","journal-title":"J Hepatol"},{"key":"3699_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12954-021-00519-y","volume":"18","author":"S Frankova","year":"2021","unstructured":"Frankova S, Jandova Z, Jinochova G, Kreidlova M, Merta D, Sperl J. Therapy of chronic hepatitis C in people who inject drugs: focus on adherence. Harm Reduct J. 2021;18:69.","journal-title":"Harm Reduct J"},{"key":"3699_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2023.12.020","volume":"80","author":"M Heo","year":"2024","unstructured":"Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, et al. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: the HERO study. J Hepatol. 2024;80:702\u201313.","journal-title":"J Hepatol"},{"key":"3699_CR32","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2352-3018(23)00267-9","volume":"11","author":"R Sacks-Davis","year":"2024","unstructured":"Sacks-Davis R, van Santen DK, Boyd A, Young J, Stewart A, Doyle JS, et al. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010\u201319: an analysis of data from a consortium of prospective cohort studies. Lancet HIV. 2024;11:e106\u201316.","journal-title":"Lancet HIV"},{"key":"3699_CR33","doi-asserted-by":"publisher","first-page":"e26048","DOI":"10.1002\/jia2.26048","volume":"25","author":"S Lodi","year":"2022","unstructured":"Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, et al. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection. J Int AIDS Soc. 2022;25:e26048.","journal-title":"J Int AIDS Soc"},{"key":"3699_CR34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/COH.0b013e32834bd365","volume":"6","author":"MD Hernandez","year":"2011","unstructured":"Hernandez MD, Sherman KE. HIV\/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS. 2011;6:478\u201382.","journal-title":"Curr Opin HIV AIDS"},{"key":"3699_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2017.07.001","volume":"62","author":"G Bruno","year":"2017","unstructured":"Bruno G, Saracino A, Scudeller L, Fabrizio C, Dell\u2019Acqua R, Milano E, et al. HCV mono-infected and HIV\/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis. 2017;62:64\u201371.","journal-title":"Int J Infect Dis"},{"key":"3699_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.29642","volume":"67","author":"C Sikavi","year":"2018","unstructured":"Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population. Hepatology. 2018;67:847\u201357.","journal-title":"Hepatology"},{"key":"3699_CR37","first-page":"117822181983584","volume":"13","author":"S Christensen","year":"2019","unstructured":"Christensen S, Buggisch P, Mauss S, B\u00f6ker KH, M\u00fcller T, Klinker H, et al. Alcohol and cannabis consumption does not diminish cure rates in a real-world cohort of chronic hepatitis C virus infected patients on opioid substitution therapy-data from the German Hepatitis C-registry (DHC-R). Subst Abuse. 2019;13:1178221819835847.","journal-title":"Subst Abuse"}],"updated-by":[{"DOI":"10.1186\/s12916-024-03753-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000}}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03699-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03699-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03699-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T07:03:39Z","timestamp":1731049419000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03699-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3699"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03699-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5024653\/v1","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12916-024-03753-w","URL":"https:\/\/doi.org\/10.1186\/s12916-024-03753-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted after the approval of the Bioethics Committee of the Jan Kochanowski University in Kielce by resolution No. 57\/2024 of 25.07.2024 r.Patients provided consent to participate in the therapeutic program according to regulations of National Health Fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Zar\u0119bska-Michaluk D has acted as a speaker for AbbVie and Gilead, Brzd\u0119k M has no conflict of interest to declare. Tronina O has no conflict of interest to declare. Janocha-Litwin J has no conflict of interest to declare. Sitko M has acted as a speaker for Gilead and AbbVie. Piekarska A has acted as a speaker and\/or advisor for AbbVie, Gilead, Merck, and Roche. Klapaczy\u0144ski J has acted as a speaker for Gilead and AbbVie. Parfieniuk-Kowerda A has no conflict of interest to declare. Barbara Sobala-Szczygie\u0142 has been a speaker for AbbVie and Gilead. Tudrujek-Zdunek M has no conflict of interest to declare. Lorenc B has no conflict of interest to declare. Flisiak R has acted as a speaker and\/or advisor, and has received funding for clinical research from AbbVie, Gilead, Merck, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"486"}}